Barchart Research What to Expect from GRFS Earnings GRFS Generated July 31, 2026 Current Price $7.87 EPS Estimate $$0.27 Consensus Rating Moderate Buy Average Move 3.84% Grifols' Transformation Narrative...
Barchart Research What to Expect from GRFS Earnings GRFS Generated July 24, 2026 Current Price $7.58 EPS Estimate $$0.28 Consensus Rating Moderate Buy Average Move 3.84% Grifols Reports Next Week With...
Grifols (NASDAQ:GRFS) executives said the company began 2026 in line with its internal plans, pointing to continued strength in immunoglobulins, early progress in expanding plasma sourcing outside the...
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Creative Medical Technology Holdings, Inc. CELZ is a commercial-stage biotechnology company. The Zacks Consensus Estimate for its...
ADMA Biologics ADMA and Grifols GRFS are leading producers of plasma-derived therapies, specializing in immunoglobulin treatments for immunodeficiencies and other conditions.ADMA Biologics markets plasma-derived...
Shares of Grifols GRFS lost over 7% on Wednesday after the company announced that Canada-based Brookfield Asset Management has withdrawn its plan to acquire it.Both parties likely failed to arrive at a...
Shares of Grifols GRFS lost over 8% on Tuesday after the company’s board refused to endorse Canada-based Brookfield Asset Management’s offer to acquire its outstanding share capital for €6.45 billion...
/PRNewswire/ -- DelveInsight's 'Dry Eye Disease Pipeline Insight – 2023' report provides comprehensive global coverage of pipeline dry eye disease therapies in...
/PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived...